Sarcoma Chemotherapy Regimens

The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option.  In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use.

Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie.

For information on open clinical trials please refer to the Cancer Trials Ireland website here and also to basket trials here.

Sarcoma Chemotherapy Regimens

 

Regimen Name Indication

Dacarbazine (1.2 g/m2) Therapy –21 day

Regimen

00511a

Treatment of metastatic soft tissue sarcoma

DOXOrubicin 75mg/m2 Monotherapy

Regimen

00500a

Treatment of locally advanced unresectable or metastatic soft tissue sarcoma.

DOXOrubicin (25mg/m2/day and CISplatin (100mg/m2) Therapy-21 day cycle

Regimen

00420a

Neoadjuvant/Adjuvant therapy of osteosarcoma.

DOXOrubicin (60) and Ifosfamide Therapy

Regimen

00391a

Treatment of locally advanced unresectable or metastatic soft tissue sarcomas.

DOXOrubicin (75) and Ifosfamide Therapy

Regimen

00392a

Neoadjuvant treatment of high risk soft tissue sarcoma.

00392b

Treatment of locally advanced unresectable or metastatic soft tissue sarcomas.

Gemcitabine and DOCEtaxel Therapy* - 21 day

Regimen

00501a

Treatment of locally advanced unresectable or metastatic soft tissue sarcoma.

Etoposide and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals

Regimen

 00675a

For the treatment of adolescents/young adults with newly diagnosed Ewing Sarcoma/ Ewing Family of tumours

00675b

For the treatment of adolescents/young adults with rhabdomyosarcoma or desmoplastic intra-abdominal small round blue cell tumour.

Etoposide and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Three Weekly Intervals

Regimen

 00747a

For the treatment of adult patients with newly diagnosed Ewing Sarcoma/ Ewing Family of tumours.

00747b

For the treatment of adult patients with rhabdomyosarcoma or desmoplastic intra-abdominal small round blue cell tumour.

Ifosfamide Etoposide (IE) Therapy

Regimen

00596a

For the treatment of relapsed Ewing Sarcoma.

00596b

For the treatment of osteosarcoma

Imatinib Therapy-GIST

Regimen

00335a

Treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).

00335b

Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.

Infusional Ifosfamide Therapy

Regimen

00679a

High grade soft tissue sarcoma, retroperitoneal and de-differentiated sarcoma

(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy

Regimen

00463a

Neoadjuvant/Adjuvant therapy of localised or metastatic high grade osteosarcoma of an extremity/axial skeleton (excluding craniofacial sites)  -all disease sites amenable to complete surgical resection

Mifamurtide

Regimen

00100a

Treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, in children, adolescents and young adults.

PAZOPanib Therapy

Regimen

00445b

Treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Pegylated Liposomal DOXOrubicin 50mg/m2 (CAELYX®) 28 days

Regimen

00205a

Monotherapy for patients with metastatic breast cancer.

00205b

Treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen

00205c

Metastatic soft tissue sarcoma

Pegylated Liposomal DOXOrubicin 20mg/m2 (CAELYX®) 21 days

Regimen

00462a

Treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts ( < 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.

Regorafenib Monotherapy

Regimen

00244b

Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.

SUNitinib 50mg Therapy

Regimen

00325a

Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.

SUNitinib 50mg (21 Days) Therapy

Regimen

00719a

Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due toresistance or intolerance.

Trabectedin Monotherapy

Regimen

00374a

Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.

vinBLAStine and Methotrexate Therapy

Regimen

00554a

Treatment of advanced aggressive fibromatosis